switching glp 1 agonists Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
Recent scientific studies have found that patients taking semaglutide significantly more likely to develop NAION than non-users a risk that the drug manufacturers did not adequately disclose
17 Similarly, in a meta-analysis of 14 RCTs in T2DM patients conducted by Liu et al, tirzepatide was shown to provide superior HbA1c reduction and improved metabolic outcomes compared to placebo, insulin, and all other GLP-1 RAs at all doses examined
doi: 10.1007/s11892-018-1011-7
Kim SY, Lee HW, Jung DK, et al
Tirzepatide versus semaglutide for weight loss: a meta-analysis of randomized controlled trials
